Showing results (601-610 of 9,400) with videos related to

Sort By:
Pageof 940
Clinical Pharmacology and Therapeutics|February 18, 1998
Reversal of endothelin-1-induced ocular hemodynamic effects by low-dose nifedipine in humansK Strenn, B Matulla, M Wolzt, et al.
Clinical Pharmacology and Therapeutics|April 23, 2023
Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model-Informed Drug Development ParadigmLan Ni, Azhar Zaman Khan, Amanda Long, et al.
Clinical Pharmacology and Therapeutics|June 1, 1986
Effects of chronic cetamolol therapy on resting, ambulatory, and exercise blood pressure and heart rateW B White, P Schulman, E J McCabe, et al.
Clinical Pharmacology and Therapeutics|January 20, 1998
The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysisD A Sica, M R Marino, J L Hammett, et al.
Clinical Pharmacology and Therapeutics|January 20, 1998
Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotypeM Tanaka, T Ohkubo, K Otani, et al.
Clinical Pharmacology and Therapeutics|January 20, 1998
Immunosuppressant pharmacodynamics on lymphocytes from healthy subjects and patients with chronic renal failure, nephrosis, and psoriasis: possible implications for individual therapeutic efficacyT Hirano, K Oka, H Takeuchi, et al.
Clinical Pharmacology and Therapeutics|January 20, 1998
A population model for the follicular growth in women treated with follicle stimulating hormoneM O Karlsson, J R Wade, E Loumaye, et al.
Clinical Pharmacology and Therapeutics|December 9, 1997
Apparent decrease in population clearance of theophylline: implications for dosageM J Asmus, M M Weinberger, G Milavetz, et al.
Clinical Pharmacology and Therapeutics|December 9, 1997
Impact of long-term ethanol consumption on CYP1A2 activityN Rizzo, E Hispard, S Dolbeault, et al.
Clinical Pharmacology and Therapeutics|December 9, 1997
Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing intervalE A Bronsky, J P Kemp, J Zhang, et al.
Pageof 940